Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSTOP: Neoadjuvant Carboplatin Regimens in TNBC
NCT02413320Phase 2Completed
- Sponsor
- Kazmira
- Start
- Jul 2015
- Primary completion
- Feb 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, docetaxel in triple-negative breast cancer (TNBC), sponsored by Kazmira. Started Jul 2015; status: completed.
02
Drugs
carboplatindocetaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02413320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413320.